Payment overview · 2025
General Payments
$279.96
15 reported records · 8 companies
Healthcare provider profile · identity verified
Rohitha Inturi, MD
Allopathic & Osteopathic Physicians|Family Medicine · LIBERAL, KS · NPI 1669762167
Verified facts
What the public records show
CMS Open Payments records show Rohitha Inturi, MD received $279.96 in general payments during 2025 across 15 reported records.
Janssen Pharmaceuticals, Inc accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $71.23 | 25.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.34 | 18.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.52 | 12.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.44 | 10.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.95 | 9.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.11 | 9.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.71 | 7.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.66 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.96 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $71.23 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 85 |
| Lisinopril | Lisinopril | 183 | 57 |
| Gabapentin | Gabapentin | 132 | 34 |
| Metformin Hcl | Metformin Hcl | 124 | 40 |
| Omeprazole | Omeprazole | 110 | 32 |
| Mounjaro | Tirzepatide | 109 | 17 |
| Ozempic | Semaglutide | 100 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 94 | 30 |
| Trazodone Hcl | Trazodone Hcl | 80 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 23 |
| Losartan Potassium | Losartan Potassium | 67 | 18 |
| Sertraline Hcl | Sertraline Hcl | 62 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 60 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 14 |
| Eliquis | Apixaban | 56 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 14 |
| Jardiance | Empagliflozin | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 23 |
| Furosemide | Furosemide | 49 | 19 |
| Potassium Chloride | Potassium Chloride | 47 | 16 |
| Montelukast Sodium | Montelukast Sodium | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 16 |
| Baclofen | Baclofen | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 15 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 11 |
| Simvastatin | Simvastatin | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 17 |
| Meloxicam | Meloxicam | 30 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Glipizide | Glipizide | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.96 · 15 records | Janssen Pharmaceuticals, Inc | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT, PREVNAR 20, SPRAVATO, TZIELD, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error